TIME TO OPIOID USE AMONG COMMERCIALLY-INSURED PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN WHO INITIATED DULOXETINE VERSUS OTHER TREATMENTS

被引：0
|
作者：
Zhao, Y. [1 ]
Chen, S. Y. [2 ]
Boulanger, L. [2 ]
Fraser, K. [2 ]
Wu, N. [2 ]
机构：
[1] Eli Lilly & Co, Indianapolis, IN 46285 USA
[2] Abt Bio Pharma Solut Inc, Lexington, MA USA
来源：
VALUE IN HEALTH | 2010年 / 13卷 / 03期
关键词：
D O I：
10.1016/S1098-3015(10)72303-2
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A65 / A65
页数：1
相关论文
共 32 条
  • [21] Real-World Versus Guideline-Based Treatments For Chronic Spontaneous Urticaria Among Commercially-Insured Versus Medicaid Patients In The United States
    Garmo, Vincent
    Seetasith, Arpamas
    Reddy, Sheila
    Chang, Eunice
    Tarbox, Marian
    Holden, Michael
    Casale, Thomas
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2023, 151 (02) : AB42 - AB42
  • [22] THE EFFECT OF MEDICATION CHOICE BETWEEN DULOXETINE AND PREGABALIN ON MEDICATION COMPLIANCE AMONG PATIENTS WITH DIABETIC PERIPHERAL NEUROPATHIC PAIN
    Sun, P.
    Zhao, Y.
    Bledsoe, S.
    Watson, P. R.
    VALUE IN HEALTH, 2009, 12 (03) : A103 - A103
  • [23] Effects of State Opioid Prescribing Laws on Use of Opioid and Other Pain Treatments Among Commercially Insured U.S. Adults (vol 175, pg 617, 2022)
    McGinty
    ANNALS OF INTERNAL MEDICINE, 2022, 175 (09) : 1342 - 1342
  • [24] Duloxetine treatment and glycemic controls in patients with diagnoses other than diabetic peripheral neuropathic pain: a meta-analysis
    Crucitti, Antonio
    Zhang, Qi
    Nilsson, Mary
    Brecht, Stephan
    Yang, Charles R.
    Wernicke, Joachim
    CURRENT MEDICAL RESEARCH AND OPINION, 2010, 26 (11) : 2579 - 2588
  • [25] Comparative Efficacy of Duloxetine Versus Nortriptyline in Patients with Diabetic Peripheral Neuropathic Pain: A Double Blind Randomized Controlled Trial
    Zakerkish, Mehrnoosh
    Amiri, Fatemeh
    Nasab, Nastaran Majdi
    Ghorbani, Ali
    IRANIAN RED CRESCENT MEDICAL JOURNAL, 2017, 19 (08)
  • [26] The treatment of patients with diabetic peripheral neuropathic pain in China: a double-blind randomized trial of duloxetine versus placebo
    Gao, Yan
    Guo, Xiaohui
    Han, Ping
    Li, Quanmin
    Yang, Gangyi
    Qu, Shen
    Yue, Li
    Wang, Chia-Ning
    Skljarevski, Vladimir
    Duenas, Hector
    Raskin, Joel
    Gu, Liqun
    DIABETES-METABOLISM RESEARCH AND REVIEWS, 2014, 30 : 30 - 31
  • [27] The Relationship Between Average Daily Dose, Medication Adherence, and Health-Care Costs among Diabetic Peripheral Neuropathic Pain Patients Initiated on Duloxetine Therapy
    Chen, Shih-Yin
    Wu, Ning
    Boulanger, Luke
    Fraser, Kimberly A.
    Zhao, Yang
    PAIN PRACTICE, 2010, 10 (06) : 530 - 539
  • [28] Effectiveness of Duloxetine versus Other Therapeutic Modalities in Patients with Diabetic Neuropathic Pain: A Systematic Review and Meta-Analysis
    Valenzuela-Fuenzalida, Juan Jose
    Lopez-Chaparro, Michelle
    Barahona-Vasquez, Marisol
    Campos-Valdes, Javiera
    Gonzalez, Javiera Cordero
    Nova-Baeza, Pablo
    Orellana-Donoso, Mathias
    Suazo-Santibanez, Alejandra
    Oyanedel-Amaro, Gustavo
    Espinoza, Hector Gutierrez
    PHARMACEUTICALS, 2024, 17 (07)
  • [29] An Open-Label, Randomized Comparison of Duloxetine, Pregabalin, and the Combination of Duloxetine and Gabapentin among Patients with Inadequate Response to Gabapentin for the Management of Diabetic Peripheral Neuropathic Pain
    Tanenberg, Robert J.
    Irving, Gordon
    Risser, Richard C.
    Ahl, Jonna
    Malcolm, Sandra
    DIABETES, 2010, 59 : A261 - A261
  • [30] COMPARISON OF HEALTHCARE RESOURCE UTILIZATION (HCRU) AND EXPENDITURES AMONG US COMMERCIALLY-INSURED PATIENTS WITH OPIOID USE DISORDER (OUD) BY TYPE OF MEDICATION-ASSISTED TREATMENT (MAT) RECEIVED
    Perry, A.
    Wing, V
    Manjelievskaia, J.
    VALUE IN HEALTH, 2019, 22 : S692 - S693
1234